Point72 Asia Singapore Pte. Ltd. Acquires Shares of 5,450 Pacira BioSciences, Inc. (NASDAQ:PCRX)

Point72 Asia Singapore Pte. Ltd. acquired a new stake in Pacira BioSciences, Inc. (NASDAQ:PCRX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 5,450 shares of the company’s stock, valued at approximately $103,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. lifted its holdings in Pacira BioSciences by 16.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 502,204 shares of the company’s stock valued at $9,462,000 after purchasing an additional 70,307 shares in the last quarter. Nisa Investment Advisors LLC increased its stake in shares of Pacira BioSciences by 495.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock worth $62,000 after acquiring an additional 2,749 shares during the last quarter. Empowered Funds LLC increased its stake in shares of Pacira BioSciences by 5.1% in the 4th quarter. Empowered Funds LLC now owns 229,485 shares of the company’s stock worth $4,323,000 after acquiring an additional 11,149 shares during the last quarter. LPL Financial LLC acquired a new stake in shares of Pacira BioSciences in the 4th quarter worth $251,000. Finally, Norges Bank acquired a new stake in shares of Pacira BioSciences in the 4th quarter worth $2,405,000. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Stock Up 1.0%

Shares of NASDAQ:PCRX opened at $25.86 on Friday. The business has a 50-day moving average price of $24.88 and a 200 day moving average price of $22.40. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $1.20 billion, a price-to-earnings ratio of -12.74 and a beta of 0.56. Pacira BioSciences, Inc. has a 12-month low of $11.16 and a 12-month high of $31.64.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. HC Wainwright raised their target price on Pacira BioSciences from $48.00 to $65.00 and gave the stock a “buy” rating in a research note on Tuesday, April 8th. Needham & Company LLC cut their target price on Pacira BioSciences from $32.00 to $30.00 and set a “buy” rating for the company in a research note on Friday, May 9th. Barclays raised their target price on Pacira BioSciences from $17.00 to $24.00 and gave the stock an “overweight” rating in a research note on Friday, February 28th. Finally, Truist Financial raised Pacira BioSciences from a “sell” rating to a “hold” rating and raised their target price for the stock from $8.00 to $25.00 in a research note on Thursday, January 30th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $26.44.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.